Prothena Corp Public (PRTA) Return on Capital Employed (2013 - 2026)
Prothena Corp Public (PRTA) posted quarterly Return on Capital Employed of 38.92% for Q1 2026, down 960.0% year-over-year from 4.53% in Q1 2025, and up 45.81% quarter-over-quarter from 71.82% in Q4 2025.
Prothena Corp Public (PRTA) Return on Capital Employed (2013 - 2026) Analysis & Trends
Prothena Corp Public's Return on Capital Employed history runs 14 years deep, the most recent figure standing at 38.92% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 960.0% year-over-year to 38.92%; the TTM figure through Mar 2026 stood at 38.92% (down 960.0% YoY), while the FY2025 annual figure was 54.19%, down 2722.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 38.92%, up from 71.82% in the prior quarter.
- The five-year high for Return on Capital Employed was 11.83% in Q1 2022, with the low at 78.71% in Q3 2025.
- The 5-year median for Return on Capital Employed is 29.3% (2024), against an average of 31.71%.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed surged 4788 bps in 2022, then slumped 5868 bps in 2025.
- Prothena Corp Public's Return on Capital Employed stood at 21.71% in 2022, then slumped by 32 bps to 28.74% in 2023, then retreated by 3 bps to 29.57% in 2024, then tumbled by 143 bps to 71.82% in 2025, then soared by 46 bps to 38.92% in 2026.
- Business Quant data shows PRTA's Return on Capital Employed at 38.92% in Q1 2026, 71.82% in Q4 2025, and 78.71% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - | -17.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.65% |
| Mar 31, 2026 | -38.92% |
| Dec 31, 2025 | -71.82% |
| Sep 30, 2025 | -78.71% |
| Jun 30, 2025 | -74.23% |
| Mar 31, 2025 | -29.32% |
| Dec 31, 2024 | -29.57% |
| Sep 30, 2024 | -29.30% |
| Jun 30, 2024 | -15.55% |
| Mar 31, 2024 | -35.07% |
| Dec 31, 2023 | -28.74% |
| Sep 30, 2023 | -16.55% |
| Jun 30, 2023 | -26.27% |
| Mar 31, 2023 | -21.39% |
| Dec 31, 2022 | -21.71% |
| Sep 30, 2022 | -32.82% |
| Jun 30, 2022 | -0.96% |
| Mar 31, 2022 | 11.83% |
| Dec 31, 2021 | 12.25% |
| Sep 30, 2021 | 14.79% |